BTI completes SUGARDOWN human clinical study on blood sugar management

Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today the completion of a trial in healthy volunteers performed at the University of Sydney on SUGARDOWN™, a dietary supplement designed to reduce post-meal elevation of blood glucose.

"We are very pleased to have completed this trial at the Sydney University Glycemic Index Research Service (SUGiRS), and delighted to have worked with Dr. Jennie Brand-Miller who conducted the trial," said Ken Tassey, President at Boston Therapeutics. This study has important endpoints that support our expectation that SUGARDOWN™ can be a powerful tool for many people who struggle with blood sugar management."

SUGARDOWN™ was tested in healthy, but overweight adults with a mean body mass index (BMI) value of 27.3 kg/m². The data were collected for postprandial blood sugar elevation with a 50g glucose challenge.

"We are in the process of summarizing the data to demonstrate the significant reduction in postprandial blood glucose after consumption of SUGARDOWN™ chewable tablets," said Joan Sellers, Ph.D., and company Chief Technology Officer.